Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 4/20 | 0.44 |
| ▸ | CES1 | P23141 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19716865 | 1.00 | TSHR (0.46) | TSHRCES2CES1ALDH1A1GAA | |
| SCHEMBL7201365 | 0.77 | CES2 (0.44) | CES2CES1ALDH1A1GAABCHE | |
| SCHEMBL27263318 | 0.77 | CES2 (0.47) | TSHRCES2CES1ALDH1A1GAA | |
| SCHEMBL2163400 | 0.76 | TSHR (0.50) | TSHRCES2CES1ALDH1A1GAA | |
| SCHEMBL3495437 | 0.76 | TSHR (0.50) | TSHRCES2CES1ALDH1A1GAA | |
| SCHEMBL27257974 | 0.74 | CES2 (0.38) | CES2CES1ALDH1A1GAA | |
| SCHEMBL954647 | 0.73 | ALDH1A1 (0.39) | CES2CES1ALDH1A1GAACYP2C9 | |
| SCHEMBL8830248 | 0.73 | TSHR (0.46) | TSHRALDH1A1GAA | |
| SCHEMBL18801012 | 0.72 | CES2 (0.52) | CES2CES1ALDH1A1BCHE | |
| SCHEMBL9665695 | 0.70 | TSHR (0.37) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040171862-A1 | Method for producing optically active cyanohydrins and their corresponding acids | CLARIANT GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171862-A1 | Method for producing optically active cyanohydrins and their corresponding acids | MVD, HPD, VNN1 | TSHR 4387/4885CES2 723/4885CES1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.